This product is a prescription item and a medical review is required for purchase.
AOD‑9604 is a synthetic peptide fragment of human growth hormone (HGH 176‑191) that was originally researched as an anti‑obesity drug.
It is designed to selectively activate the fat‑burning pathways associated with growth hormone while avoiding its broader growth and blood‑sugar effects.
Clinical studies suggest AOD‑9604 can modestly enhance fat breakdown and support body composition when used alongside nutrition and lifestyle interventions.
It is not FDA‑approved for weight loss; use is based on practitioner discretion and current clinical evidence.
When used as directed and alongside a healthy lifestyle, clients commonly use AOD‑9604 to help support:
Fat‑burning & body shaping
Supporting the body’s natural ability to break down stored fat, especially when combined with a balanced diet and regular movement.
Waistline & body‑composition goals
Helping to complement a structured weight‑management plan, with a focus on changes in body shape rather than just the number on the scale.
Lifestyle & metabolic support
Working alongside nutrition, exercise and sleep strategies to support overall metabolic health and long‑term results.
Confidence in an active lifestyle
Providing an extra layer of support for people who are already taking steps to improve their health, energy and body composition.
*Individual results vary. AOD‑9604 works best as part of a comprehensive plan created with your healthcare provider and is not a substitute for healthy nutrition, movement or medical care.
| UAE Made | Vegan Friendly | Gluten Free | Corn Free |
| Y | Y | Y | Y |
| Dairy Free | Soy Free | Shellfish Free | No Egg Products |
| Y | Y | Y | Y |
| Ingredient name | Description |
|---|---|
| AOD 2000mcg/mL | AOD‑9604 (HGH fragment 176‑191) |
AOD‑9604 (HGH fragment 176‑191) – dose per vial as compounded by partner pharmacy/clinic.
Sterile diluent (e.g., bacteriostatic saline) and standard compounding excipients as specified by the partner pharmacy (may include buffering agents and preservatives).
Subcutaneous injection into fatty tissue (e.g., lower abdomen or outer thigh), using an insulin type syringe, as instructed by a healthcare professional.
Timing & Frequency
Once Daily upon waking on an empty stomach (pre exercise where possible).
Administration Method:
Subcutaneous (SC) injection using an insulin syringe into fatty tissue (e.g., lower abdomen or outer thigh), as instructed by a healthcare professional.
Duration of Standard Course
Standard Dosing Increase
Common Side Effects and Adverse Reactions
Typically mild and transient but can include:
Reactions Requiring Medical Attention
Patients should stop injections and contact their healthcare provider (or emergency services, if severe) if they experience:
Safety Note: Long‑term data are limited; use should always be monitored by a qualified clinician, with regular review of metabolic markers and overall treatment goals.